Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

CoolSculpting and EMS for the Abdomen (ECA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03738891
Recruitment Status : Completed
First Posted : November 13, 2018
Last Update Posted : August 18, 2020
Sponsor:
Information provided by (Responsible Party):
Zeltiq Aesthetics

Brief Summary:
Evaluate the use of Electromagnetic Muscle Stimulation as an adjunctive treatment to CoolSculpting.

Condition or disease Intervention/treatment Phase
Body Fat Disorder Device: The ZELTIQ System Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Feasibility Study to Evaluate Electromagnetic Muscle Stimulation and CoolSculpting for Abdominal Contouring
Actual Study Start Date : November 7, 2018
Actual Primary Completion Date : September 9, 2019
Actual Study Completion Date : September 9, 2019

Arm Intervention/treatment
Experimental: Fat Reduction
The treatments are designed to see if the fat can be reduced in the abdomen.
Device: The ZELTIQ System
The CoolSculpting machine will be used to perform the treatments.




Primary Outcome Measures :
  1. Safety endpoint in relation to adverse events [ Time Frame: Final post treatment 1 day visit ]
    Measurement of device- or procedure-related adverse events.

  2. Effectiveness endpoint gauged by photographs [ Time Frame: Final post treatment 1 day visit ]
    Comparison of pre-treatment- and 12-week post-final treatment photographs to assess visible changes in the abdomen.


Secondary Outcome Measures :
  1. 3-D imaging [ Time Frame: Final post treatment 1 day visit ]
    Reduction in abdominal circumference as measured by 3-Dimensional imaging.

  2. Global Aesthetic Improvement Scale (GAIS) [ Time Frame: Final post treatment 1 day visit ]
    Subject- graded GAIS at 12-week post-final treatment follow-up.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria

  • Male and female subjects > 22 years of age and ≤65 years of age.
  • Subject has not had weight change exceeding 5% of body weight in the preceding month.
  • Subject agrees to maintain her weight (i.e., within 5%) by not making any major changes in diet or exercise routine during the course of the study.
  • Subject agrees to refrain from any new abdominal training exercises during the course of the study.
  • BMI ≤ 30 kg/m2 as determined at screening.
  • Abdominal skin fold thickness 2.0 to 5.0 cm, as measured by caliper below umbilicus.
  • Subject has read and signed a written informed consent form.

Exclusion Criteria

  • Subject has had a surgical procedure(s) in the area of intended treatment.
  • Subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment.
  • Subject has had a non-invasive fat reduction, body contouring and/or skin tightening procedure in the area of intended treatment within the past 12 months.
  • Subject has numbness, tingling or other altered sensation in the treatment area.
  • Subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.
  • Subject has not had an intrauterine contraceptive device inserted or removed within the past month.
  • Subject has a known history of cryoglobulinemia, cold urticaria, cold agglutinin disease, or paroxysmal cold hemoglobinuria
  • Subject has a known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin.
  • Subject has a history of bleeding disorder or is taking any medication that in the Investigator's opinion may increase the subject's risk of bruising.
  • Subject has known sensitivity or allergy to isopropyl alcohol and propylene glycol, or latex.
  • Subject is taking or has taken diet pills or supplements within the past month.
  • Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites, that may interfere with the treatment or evaluation (stretch marks is not an exclusion).
  • Subject has a metal implant or active implanted device such as a pacemaker, defibrillator, or drug delivery system.
  • Subject has been involved in any type of abdominal muscle training program within the previous 6 months.
  • Subject has pulmonary insufficiency.
  • Subject has a cardiac disorder.
  • Subject has a malignant tumor.
  • Subject has been diagnosed with epilepsy.
  • Subject currently has a fever.
  • Subject is pregnant or intending to become pregnant during the study period (in the next 9 months).
  • Subject is lactating or has been lactating in the past 6 months.
  • Subject is unable or unwilling to comply with the study requirements.
  • Subject is currently enrolled in a clinical study of any other investigational drug or device.
  • Any other condition or laboratory value that would, in the professional opinion of the Investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03738891


Locations
Layout table for location information
United States, California
Marina Plastic Surgery
Marina Del Rey, California, United States, 90292
Innovation Research Center
Pleasanton, California, United States, 94588
Laser & Skin Surgery Center of Northern California
Sacramento, California, United States, 95816
United States, North Carolina
Aesthetic Solutions, P.A.
Chapel Hill, North Carolina, United States, 27517
Sponsors and Collaborators
Zeltiq Aesthetics
Investigators
Layout table for investigator information
Study Director: Kerrie Jiang, NP Zeltiq Aesthetics
Layout table for additonal information
Responsible Party: Zeltiq Aesthetics
ClinicalTrials.gov Identifier: NCT03738891    
Other Study ID Numbers: ZA18-003
First Posted: November 13, 2018    Key Record Dates
Last Update Posted: August 18, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lipid Metabolism Disorders
Metabolic Diseases